Biopharma co Veru tumbles on planned stock-and-warrants offering
Skye's obesity drug misses mid-stage trial main goal, shares tank (updated)
U.S. RESEARCH ROUNDUP -ANI Pharmaceuticals, Berkshire Hathaway, Chevron
Veru Inc reports results for the quarter ended June 30 - Earnings Summary
Veru Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Veru Announces Reverse Stock Split
Veru Inc expected to post a loss of 5 cents a share - Earnings Preview
Brief: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says
Factbox: Fat, not muscle: Drugmakers in race for next weight-loss breakthrough
U.S. STOCKS ON THE MOVE-Nvidia, Salesforce, Kestrel Group
U.S. STOCKS ON THE MOVE-Dick's Sporting Goods, Sonic Automotive
U.S. STOCKS ON THE MOVE-Abercrombie & Fitch, Boston Scientific, DoorDash
Brief: Veru Reports Positive Safety Results From Phase 2B Quality Study
U.S. STOCKS ON THE MOVE-Veru, GameStop, Azul
Veru rises as combo drug shows fewer side effects than semaglutide alone in trial
Veru Inc reports results for the quarter ended March 31 - Earnings Summary
Veru Inc expected to post a loss of 6 cents a share - Earnings Preview
Veru Inc expected to post a loss of 6 cents a share - Earnings Preview